Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07399977 · ClinicalTrials.gov registry record · NA

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

A NA study of Venous Thromboembolism and Deep Venous Thrombosis, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
NA
Development phase
259
Enrollment target
8
Study locations

NCT07399977 is a NA study of Venous Thromboembolism and Deep Venous Thrombosis that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 259 participants, below the 6,290-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07399977, a NA study of Venous Thromboembolism and Deep Venous Thrombosis, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
NA
Development phase
259 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.

Conditions Studied

Venous Thromboembolism Deep Venous Thrombosis

Interventions

  • DIAGNOSTIC_TEST MSK-ACCESS
  • DIAGNOSTIC_TEST ctDNA/VTE Risk Score:

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
  • Memorial Sloan Kettering Nassau (All protocol activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Other

  • Royal North Shore Hospital, Australia - Sydney

Trial Details

FieldValue
Enrollment Target 259 participants
Start Date 2026-01-30
Est. Completion 2030-01-30
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07399977

The ClinicalTrials.gov registry entry for NCT07399977 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,290-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 2 interventions - of which MSK-ACCESS is the first listed.

NCT07399977 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Other.

Frequently Asked Questions

What is clinical trial NCT07399977 about?

NCT07399977 is a clinical study titled "Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism". The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.

What is the current status of trial NCT07399977?

This trial is currently recruiting. It is a NA study. The enrollment target is 259 participants. The study started on 2026-01-30. Estimated completion is 2030-01-30.

What conditions does trial NCT07399977 study?

This clinical trial studies the following conditions: Venous Thromboembolism, Deep Venous Thrombosis.

What interventions are being tested in trial NCT07399977?

The interventions under investigation include: MSK-ACCESS (DIAGNOSTIC_TEST), ctDNA/VTE Risk Score: (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07399977?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07399977 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Venous Thromboembolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Venous Thromboembolism

All registered trials for this condition

Deep Venous Thrombosis

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.